Bayer (BYR.L,BAYRY.PK,BAYZF.PK,BAY.MI,BAYN.DE) announced that the European Commission has granted approval in the European Union for Kerendia or finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist for the treatment of adults with heart failure with left ventricular ejection fraction =40%. In the EU, Kerendia is now indicated for the treatment of symptomatic chronic heart failure with LVEF =40% in adults, expanding its use beyond the existing indication in patients with chronic kidney disease associated with type 2 diabetes.
The approval by the European Commission is based on the positive results from the pivotal Phase III FINEARTS-HF study.
At last close, Bayer shares were trading at 38.26 euros.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.